Modality
Radioligand
MOA
CFTRmod
Target
MDM2
Pathway
STING
LNRBPAH
Development Pipeline
Preclinical
Oct 2017
→ Jun 2027
PreclinicalCurrent
NCT05567152
2,761 pts·LN
2023-02→2026-02·Recruiting
NCT04193181
1,613 pts·LN
2017-10→2027-06·Completed
4,374 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-012mo agoInterim· LN
2027-06-281.2y awayInterim· LN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
Preclinical
Complet…
Preclinical
Recruit…
Catalysts
Interim
2026-02-01 · 2mo ago
LN
Interim
2027-06-28 · 1.2y away
LN
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05567152 | Preclinical | LN | Recruiting | 2761 | OS |
| NCT04193181 | Preclinical | LN | Completed | 1613 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 |